IP Library › Granted Patent US 12,357,604
Granted Patent B2
US 12,357,604 · App. 16/649,119 · Granted Jul 15, 2025

Topical formulations of cannabinoids and use thereof in the treatment of pain

Inventors: Hayes Wong (North Vancouver, CA); Sazzad Hossain (Richmond, CA); Brian Cairns (Vancouver, CA); Karen Ann Long (Vancouver, CA); Alexandra Mancini (West Vancouver, CA)
Assignee: INMED PHARMACEUTICALS INC.
A61K31/352A61K31/01A61K31/045A61K31/05A61K31/08A61K31/343A61K31/397A61K31/415A61K31/4178A61K45/06A61K47/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,357,604
App. No.
16/649,119
Granted
Jul 15, 2025
Kind
B2
Abstract

Pharmaceutical compositions comprising one or more cannabinoids and a pharmaceutically acceptable carrier are disclosed. The compositions are in a form suitable for topical administration, and are useful in the treatment of pain. The cannabinoids suitable for use include cannabidiols, cannabinols, and various other naturally occurring and synthetic cannabinoids. The compositions may also further include anti-inflammatory agents, steroids, or terpenoids. In preferred embodiments, the cannabinoids incorporated in the compositions are cannabidiol (CBD) and cannabinol (CBN) while the carriers are selected from the group consisting of Labrasol™, Transcutol™, lecithin, lysolecithin, isopropyl palmitate, and isopropyl myristate.

Claims (11)

1. A pharmaceutical composition for treating pain, the pharmaceutical composition comprising:

a. a therapeutically effective quantity of a mixture of one or more cannabidiols and cannabinol in a ratio of 5:1 μM,

wherein the therapeutically effective quantity of the mixture is an amount that induces no or substantially no psychoactive effect when administered by topical administration and is sufficient to reduce or reverse pain and/or central sensitization; and

b. at least one pharmaceutically acceptable carrier for topical administration of the pharmaceutical composition, wherein the pharmaceutical carrier comprises caprylocaproyl polyoxy-8 glycerides, poloxamer 407, lecithin, and isopropyl palmitate, and

wherein the pharmaceutical composition is a topical formulation.

2. The pharmaceutical composition of claim 1 , wherein said therapeutically effective quantity is an amount sufficient to increase a mechanical threshold in peripheral nerve fibers of the area treated by topical administration, reduce or eliminate hyperalgesia in the area treated by topical administration, or reduce or eliminate allodynia in the area treated by topical administration.

3. The pharmaceutical composition of claim 1 , wherein the one or more cannabidiols are selected from the group consisting of: (i) Δ 5 -cannabidiol (2-(6-isopropenyl-3-methyl-5-cyclohexen-1-yl)-5-pentyl-1,3-benzenediol); (ii) Δ 4 -cannabidiol (2-(6-isopropenyl-3-methyl-4-cyclohexen-1-yl)-5-pentyl-1,3-benzenediol); (iii) Δ 3 -cannabidiol (2-(6-isopropenyl-3-methyl-3-cyclohexen-1-yl)-5-pentyl-1,3-benzenediol); (iv) Δ 3,7 -cannabidiol (2-(6-isopropenyl-3-methylenecyclohex-1-yl)-5-pentyl-1,3-benzenediol); (v) Δ 2 -cannabidiol(2-(6-isopropenyl-3-methyl-2-cyclohexen-1-yl)-5-pentyl-1,3benzenediol); and (vi) Δ 1 -cannabidiol (2-(6-isopropenyl-3-methyl-1-cyclohexen-1-yl)-5-pentyl-1,3benzenediol); and (vii) Δ 6 -cannabidiol (2-(6-isopropenyl-3-methyl-6-cyclohexen-1-yl)-5-pentyl-1,3-benzenediol).

4. The pharmaceutical composition of claim 1 , comprising an additional therapeutically active agent selected from the group consisting of a topical anti-inflammatory agent, and a topical steroid, or further comprising a therapeutically effective quantity of a terpenoid, wherein the terpenoid is selected from the group consisting of borneol, carvophyllene, 1,8-cineol, p-cymene, fenchone, α-humulene, kaempferol, limonene, linoleic acid, α-linolenic acid, luteolin, β-myrcene, oleic acid, orientin, α-pinene, phytol, quercetin, selinene, sitosterol, terpinenol-4, N-trans-caffeoyltyramine, N-trans-coumaroyltyramine, N-trans-ferruloyltyramine, and vitexin.

5. The pharmaceutical composition of claim 4 , wherein the terpenoid is borneol, 3-myrcene, or a combination of borneol and 3-myrcene.

6. A method for treating pain in a subject in need thereof, the method comprising topical application of a pharmaceutical composition according to claim 1 to a mammalian subject in need thereof.

7. The method of claim 6 , wherein said pain is muscle pain.

Continuity (2)
Provisional Application 62562166 · Sep 22, 2017
Related Publication 20200289458A1 · Sep 17, 2020
References Cited (91)
US 6284788B1 · Mittendorf et al. · 2001 [cited by applicant]
US 6573292B1 · Nardella · 2003 [cited by applicant]
US 6825209B2 · Thomas et al. · 2004 [cited by applicant]
US 6921722B2 · Ogure et al. · 2005 [cited by applicant]
US 7109216B2 · Kruse et al. · 2006 [cited by applicant]
US 7294645B2 · Barth et al. · 2007 [cited by applicant]
US 7314886B2 · Chao et al. · 2008 [cited by applicant]
US 7446122B2 · Chao et al. · 2008 [cited by applicant]
US 7504522B2 · Davidson et al. · 2009 [cited by applicant]
US 7700634B2 · Adam-Worrall et al. · 2010 [cited by applicant]
US 8778950B2 · Jones et al. · 2014 [cited by applicant]
US 9133128B2 · Fulp et al. · 2015 [cited by applicant]
US 9173867B2 · Travis · 2015 [cited by applicant]
US 9284303B2 · Gijsen et al. · 2016 [cited by applicant]
US 9376367B2 · Herkenroth et al. · 2016 [cited by applicant]
US 9394267B2 · Attala et al. · 2016 [cited by applicant]
US 20050266061A1 · Stinchcomb et al. · 2005 [cited by applicant]
US 20100035978A1 · Guy · 2010 [cited by examiner]
US 20100273895A1 · Stinchcomb et al. · 2010 [cited by applicant]
US 20150126595A1 · Smith · 2015 [cited by applicant]
US 20150297556A1 · Smith · 2015 [cited by examiner]
US 20160303039A1 · Smith · 2016 [cited by examiner]
US 20200197357A1 · Touitou · 2020 [cited by examiner]
EP 1588697A1 · 2005 [cited by examiner]
EP 1645270B1 · 2006 [cited by applicant]
WO WO2005120478A1 · 2005 [cited by applicant]
WO WO2006111424A1 · 2006 [cited by applicant]
WO WO2007001891A1 · 2007 [cited by examiner]
WO WO2007148094A1 · 2007 [cited by applicant]
WO WO2010013240A1 · 2010 [cited by applicant]
WO WO2010126501A1 · 2010 [cited by applicant]
WO WO2012160358A1 · 2012 [cited by applicant]
WO WO2015068052A2 · 2015 [cited by applicant]
WO WO2016090287A2 · 2016 [cited by applicant]
WO WO2016090287 · 2016 [cited by examiner]
WO WO2017055846A1 · 2017 [cited by applicant]
WO WO2017158539A1 · 2017 [cited by applicant]
WO WO2017190249A1 · 2017 [cited by applicant]
Cumella et al. (ChemMedChem, 7: 452-463, 2012). [cited by examiner]
Amaya et al., “Induction of CB1 cannabinoid receptor by inflammation in primary neurons facilitates antihyperalgesic effect of peripheral CB1 agonist”, Pain, vol. 124(1-2), pp. 175-183 (2006). [cited by applicant]
Annoymous, “CBD For Skin Conditions—Cannabidiol Salve, Balms, Creams”, buycbdoilonline, Jun. 13, 2014, pp. 1-8; (URL:http://www.buycbdoilonline. Info/2014/06/cbd-skin-conditions), Retrieved from the Internet on Jan. 31,… [cited by applicant]
Appendino G et al. “Antibacterial cannabinoids from [cited by applicant]
Booker et al., “Evaluation of Prevalent Phytocannabinoids in the Acetic Acid Model of Visceral Nociception”, Drug Alcohol Depend, vol. 105(1-2), pp. 42-47 (2009). [cited by applicant]
Bose et al., “Two Mechanisms Regulate Keratin K15 Expression In Keratinocytes: Role of PKC/AP-1 and FOXM1 Mediated Signalling”, PLoS One, vol. 7(6):e38599 (2012). [cited by applicant]
Boukamp et al., “Normal keratinization in a spontaneously immortalized aneuploidy human keratinocyte cell line”, J. of Cell Biology, vol. 106, pp. 761-771 (1988). [cited by applicant]
Chen et al., “Organ-level quorum sensing directs regeneration in hair stem cell populations”, Cell, vol. 161(2), pp. 277-290 (2015). [cited by applicant]
Coulombe et al., “Epidermolysis bullosa simplex: a paradigm for disorders of tissue fragility”, J of Clinical Investigation, vol. 119(7), pp. 1784-1793 (2009). [cited by applicant]
Cosmetic Bench Reference 1996, Cosmetics & Toiletries, published by Allured Publishing Corporation, pp. 1.19-1.22 (1996). [cited by applicant]
Dvorak et al., “Histamine induced responses are attenuated by cannabinoid receptor agonist in human skin”, Inflamm. Res., vol. 52, pp. 238-245 (2003). [cited by applicant]
Feng et al., “Antagonism of cannabinoid receptor 2 pathway suppresses IL-6-induced immunoglobulin IgM secretion”, BMC Pharmacol Toxicol, 15:30 (2014). [cited by applicant]
Formukong et al., “Analgesic and Antiinflammatory Activity of Constituents of [cited by applicant]
Gaffal et al., “Anti-inflammatory activity of topical THC in DNFB-mediated mouse allergic contact dermatitis independent of CB1 and CB2 receptors”, Allergy, 68(8):994-1000 (2013). [cited by applicant]
Gardner et al., “Autocrine and paracrine regulation of lymphocyte CB2 receptor expression by TGF-beta”, Biochem Biophys Res Commun., 290(1):91-6 (2002). [cited by applicant]
Hatzfeld, M & Franke, WW, “Pair Formation and Promiscuity of Cytokeratins: Formation in Vitro of Heterotypic Complexes and Intermediate-sized Filaments by Homologous and Heterologous Recombinations of Purified Polypepti… [cited by applicant]
Howlett et al., “International Union of Pharmacalogy. XXVII. Classification of Cannabinoid Receptors”, Pharmacolgical Reviews, vol. 54, pp. 161-202 (2002). [cited by applicant]
InMed Pharmaceuticals, “InMed Expands Pipeline with Initiation of Program Targeting Epidermolysis bullosa simples (EBS)”, Feb. 3, 2015. [cited by applicant]
InMed Pharmaceuticals, “InMed provides update on progress of its development program for epidermolysis bullosa”, Nov. 4, 2015, retrieved from https://www.inmedpharma.com/news-media/news/2015/inmed-provides-updated-on-pr… [cited by applicant]
Khilnani, G. and Khilnani, A. K., “Inverse Agonism and its therapeutic significance”, Indian J. Pharmacol., vol. 43(5), pp. 492-501 (2011). [cited by applicant]
Kozela E et al., “Cannabinoids decrease the th17 inflammatory autoimmune phenotype”, J Neuroimmune Pharmacol., 8(5):1265-76 (2013). [cited by applicant]
Lettner et al., “MMP-9 and CXCL8/IL-8 Are Potential Therapeutic Targets in Epidermolysis Bullosa Simplex”, PLoS One, 8(7):e703 (2013). [cited by applicant]
Lloyd et al. “The Basal Keratin Network of Stratified Squamous Epithelia: Defining K15 Function in the Absence of K14”, J Cell Biol., 129: 1329-1344 (1995). [cited by applicant]
Lodzki et al., “Canabidiol-transdermal delivery and anti-inflammatory effect in a murine model”, Journal of Controlled Release, vol. 93, pp. 377-387 (2003). [cited by applicant]
Mazzalupo et al., “Role for Keratins 6 and 17 During Wound Closure in Embryonic Mouse Skin”, Dev Dyn. 226(2): 356-65 (2003). [cited by applicant]
Paladini et al., “Onset of re-epithelialization after skin injury correlates with a reorganization of keratin filaments in wound edge keratinocytes: defining a potential role for keratin 16”, Journal of cell biology, 13… [cited by applicant]
Paudel et al, “Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers”, Drug Development and Industrial Pharmacy, vol. 36, No. 9, pp. 1088-1097 (2010) Perinatology, vol. 44, … [cited by applicant]
Perinatology, vol. 44, No. 2, p. 243-245 (2014). [cited by applicant]
Pini et al., “The role of cannabinoids in inflammatory modulation of allergic respiratory disorders, inflammatory pain and ischemic stroke”, Curr Drug Targets, 13(7):984-93 (2012). [cited by applicant]
Pucci et al., “Epigenetic control of skin differentiation genese by phytocannabinoids”, British Journal of Pharmacology, vol. 170, No. 3, pp. 581-591 (2013). [cited by applicant]
Radoja et al., Thyroid Hormones and Gamma Interferon Specifically Increase K15 Keratin Gene Transcription, Mol Cell Biol:, 24(8): 3168-3179 (2004). [cited by applicant]
Ramot et al., “A novel control of human keratin expression: cannabinoid receptor 1-mediated signaling down-regulates the expression of keratins K6 and K16 in human keratinocytes in vitro and in situ”, Peer J. 19;1:e40 (… [cited by applicant]
Rawal et al., “Effect of cannabidiol on human gingival fibroblast extracellular matrix metabolism: MMP production and activity, and production of fibronectin and transforming growth factor b”, J Periodontal Res., 47(3):… [cited by applicant]
Richardson et al., “Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors”, Pain, 75(1):111-9 (1998). [cited by applicant]
Roth et al., “Cytokines as genetic modifiers in K5−/− mice and in human epidermolysis bullosa simplex”, Hum Mutat, 30(5):832-41 (2009). [cited by applicant]
Rotty and Coulombe, “A wound-induced keratin inhibits Src activity during keratinocyte migration and tissue repair”, Journal of Cell Biology, 197:381-389 (2012). [cited by applicant]
Rueda et al., “The CB1 Cannabinoid Receptor Is Coupled to the Activation of c-Jun N-Terminal Kinase”, Mol Pharmacol., 58(4):814-20 (2000). [cited by applicant]
Ständer et al., “Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus”, Hautarzt., 57(9):801-7 (2006). [cited by applicant]
Stinchcomb et al., “Human skin permeation of Δ8-tetrahydrocannibonal cannabidiol and cannabinol”, J. of Pharmacy and Pharmacology, vol. 56, pp. 291-297 (2004). [cited by applicant]
Soderstrom et al., “Cannabinoids Modulate Neuronal Activity and Cancer by CB1 and CB2 Receptor-Independent Mechanisms”, Frontiers in Pharmacology, vol. 8(720), pp. 1-28 (2017). [cited by applicant]
Teixeira-Clerc et al., “CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis”, Nat Med., 12(6):671-6 (2006). [cited by applicant]
Toth et al., “Endocannabinoids modulate human epidermal keratinocyte proliferation and survival via the sequential engagement of cannabinoid receptor-1 and transient receptor potential vanilloid-1”, Journal of Investiga… [cited by applicant]
Turner CE and Elsohly MA, “Biological activity of cannabichromene, its homologs and isomers”, J Clin Pharmacol., 21(8-9 Suppl):283S-291S (1981). [cited by applicant]
Uitto et al., “Progress toward Treatment and Cure of Epidermolysis Bullosa: Summary of the DEBRA International Research Symposium EB2015”, Journal of Investigative Dermatology, vol. 136, No. 2, pp. 352-358 (2016). [cited by applicant]
Wagner et al., “Gene expression analysis of an epidermolysis bullosa simplex Dowling-Meara cell line by subtractive hybridization: recapitulation of cellular differentiation, migration and wound healing”, Exp Dermatol.,… [cited by applicant]
Wagner et al., “Imbalance of intermediate filament component keratin 14 contributes to increased stress signalling in epidermolysis bullosa simplex”, Exp Dermatol., 22(4):292-4 (2013). [cited by applicant]
Waseem et al., “Keratin 15 Expression in Stratified Epithelia: Downregulation in Activated Keratinocytes”, J Invest Dermatol., 112, 362-369 (1999). [cited by applicant]
Werner S and Munz B, “Suppression of keratin 15 expression by transforming growth factor beta in vitro and by cutaneous injury in vivo”, Exp Cell Res., 254(1):80-90 (2000). [cited by applicant]
Wong and Coulombe, “Loss of keratin 6 (K6) proteins reveals a function for intermediate filaments during wound repair”, J Cell Biol., 163(2): 327-337 (2003). [cited by applicant]
Wong et al., “Delta-9-tetrahydrocannabinol decreases masticatory muscle sensitization in female rats through peripheral cannabinoid receptor activation”, European J. of Pain, vol. 21, pp. 1732-1742 (2017). [cited by applicant]
Yang et al., “Effect of chronic CB1 cannabinoid receptor antagonism on livers of rats with biliary cirrhosis”, Clin Sci (Lond)., 112(10):533-42 (2007). [cited by applicant]
Yoshimura et al., “Non-Myeloid Cells are Major Contributors to Innate Immune Responses via Production of Monocyte Chemoattractant Protein-1/CCL2”, Front Immunol., 4(482):1-6 (2014). [cited by applicant]
Zhang et al., “FSP1+ fibroblasts promote skin carcinogenesis by maintaining MCP-1-mediated macrophage infiltration and chronic inflammation”, Am J. Pathol., 178(1):382-90 (2011). [cited by applicant]